Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases
ConclusionsOmalizumab improved asthma control in some patients with EGPA with uncontrolled asthma by reducing asthma exacerbations and oral steroid requirement. However, more data are needed before recommending widespread use of omalizumab in patients with EGPA.
Source: World Allergy Organization Journal - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Corticosteroid Therapy | Skin | Skin Biopsy | Study | Vasculitis | Xolair